Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis (original) (raw)
Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation
Edmund Li
Clinical Rheumatology, 2007
View PDFchevron_right
Methotrexate Reduced TNF Bioactivity in Rheumatoid Arthritis Patients Treated with Infliximab
Hubert Marotte
Mediators of Inflammation, 2017
View PDFchevron_right
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy
Steven Hua
Arthritis research & therapy, 2018
View PDFchevron_right
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
Paul Emery
Arthritis & Rheumatism, 2004
View PDFchevron_right
Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
S. Sazliyana, Sakthiswary Rajalingham
Journal of Clinical Medicine Research, 2011
View PDFchevron_right
A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment
Patrick Verschueren
Annals of the Rheumatic Diseases, 2004
View PDFchevron_right
Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J)
Yoshiya Tanaka
Modern Rheumatology, 2008
View PDFchevron_right
Infliximab treatment of rheumatoid arthritis
Ravinder Maini
Rheumatic Disease Clinics of North America, 2004
View PDFchevron_right
Infliximab in the treatment of rheumatoid arthritis
Aleth Perdriger
Aging Health, 2006
View PDFchevron_right
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
farideh Alasti
Arthritis research & therapy, 2018
View PDFchevron_right
Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis
Charles Pritchard
The Journal of rheumatology, 2007
View PDFchevron_right
Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone
Patrick Verschueren
Arthritis & Rheumatism, 2007
View PDFchevron_right
Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results
Yuji Nozaki
Biologics: Targets and Therapy, 2018
View PDFchevron_right
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
Sofia Ernestam, Kristina Forslind
The Lancet, 2009
View PDFchevron_right
Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit
Prodromos Sidiropoulos
Annals of the Rheumatic Diseases, 2004
View PDFchevron_right
patients with rheumatoid arthritis Double-blinded infliximab dose escalation in
Mahboob Rahman
2010
View PDFchevron_right
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
Paul Emery
Rheumatology, 2007
View PDFchevron_right
Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor
A. Signore, Fabrizio Conti, R. Priori
Annals of the Rheumatic Diseases, 2008
View PDFchevron_right
Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab
P. Gaudin
Annals of the Rheumatic Diseases, 2005
View PDFchevron_right
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
William Stohl
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
The effectiveness of anti–tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study
Axel Finckh
Arthritis & Rheumatism, 2006
View PDFchevron_right
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab
Hubert Marotte
Arthritis Research & Therapy, 2007
View PDFchevron_right
74-WEEK Follow-Up of Safety of Infliximab in Patients with Refractory Rheumatoid Arthritis
isabelle delabaye
Arthritis Research & Therapy, 2010
View PDFchevron_right
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial
Alberto Berman
Arthritis & Rheumatism, 2006
View PDFchevron_right
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity
Herman Mielants
Arthritis research & therapy, 2006
View PDFchevron_right
Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study
Anastasia Zikou
Annals of the Rheumatic Diseases, 2004
View PDFchevron_right
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
Alfons Den Broeder
Annals of the Rheumatic Diseases, 2008
View PDFchevron_right
Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis
Hasan Yazici
Clinical and experimental rheumatology
View PDFchevron_right
A long-term prospective study of the use of methotrexate in rheumatoid arthritis
Joel Kremer
Arthritis & Rheumatism, 1988
View PDFchevron_right
Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
Alberto Berman
Annals of the Rheumatic Diseases, 2007
View PDFchevron_right
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
Brodszky Valentin
The European journal of health economics : HEPAC : health economics in prevention and care, 2014
View PDFchevron_right
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity
Patrick Durez
Arthritis Research & Therapy, 2010
View PDFchevron_right
Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis
Kenneth Falchuk
Arthritis & Rheumatism, 1992
View PDFchevron_right
Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
Axel Finckh
Annals of the Rheumatic Diseases, 2012
View PDFchevron_right
The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study
Paco Welsing
Rheumatology, 2005
View PDFchevron_right